Elicio Therapeutics enters $100M ATM facility; terminates prior $40M JonesTrading ATM

Elicio Therapeutics, Inc.

Company entered ATM sales agreement to sell up to $100M of common stock through B. Riley Securities, JonesTrading, and Ladenburg Thalmann.
Agents will receive 3% commission on gross proceeds from any shares sold under the program.
Company terminated prior $40M ATM agreement with JonesTrading from June 2024, effective immediately.
Sales will be made at-the-market on Nasdaq under existing S-3 registration statement.
Company not obligated to sell any shares; program provides capital raising flexibility.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Elicio Therapeutics, Inc. terminated Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC (effective 2026-03-16).

Action: termination
Agreement: atm program
Counterparty: JonesTrading Institutional Services LLC
Effective: 2026-03-16

Exact text from the filing

On March 16, 2026, the Company delivered written notice to Jones to terminate the Jones Sales Agreement and the offering of shares contemplated thereby, effective upon delivery, pursuant to Section 12(b) of the Jones Sales Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Elicio Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. valued at $100.0 million (effective 2026-03-16).

Action: entry
Agreement: atm program
Counterparty: B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc.
Value: $100.0 million
Effective: 2026-03-16

Exact text from the filing

On March 16, 2026, Elicio Therapeutics, Inc. (the “ Company ”) entered into an At Market Issuance Sales Agreement (the “ Sales Agreement ”) with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. (the “ Agents ”) with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share (the “ Common Stock ”), having an aggregate offering price of up to $100.0 million

View on SEC.gov

314 material agreements filed in the last 30 days. Browse all material agreements →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-26-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.